Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELTEMI benralizumab safety extension in adults with asthma
2015-005396-25Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of benralizumab in asthma (2 arms), sponsored by AstraZeneca. Primary endpoint: Number of adverse events and serious adverse events. Started Mar 2016; status: completed.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-005396-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005396-25.